Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Acquisitions & Divestments (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $47.4 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 60.01% year-over-year to $47.4 million; the TTM value through Dec 2025 reached $259.5 million, down 37.19%, while the annual FY2025 figure was $259.5 million, 37.19% down from the prior year.
  • Change in Acquisitions & Divestments reached $47.4 million in Q4 2025 per TRDA's latest filing, down from $75.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $123.9 million in Q1 2024 and bottomed at $1.7 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $63.9 million, with a median of $68.8 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 3575.61% in 2023, then tumbled 60.01% in 2025.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $19.5 million in 2022, then surged by 456.62% to $108.5 million in 2023, then grew by 9.17% to $118.5 million in 2024, then crashed by 60.01% to $47.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $47.4 million in Q4 2025, $75.5 million in Q3 2025, and $50.6 million in Q2 2025.